# DISC-3405 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/disc-3405

> The next catalyst for DISC-3405, sponsored by Disc Medicine, Inc. (IRON), is its primary completion, July 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | DISC-3405 |
| Codes | DISC-3405, MWTX-003 |
| Sponsor | Disc Medicine, Inc. (IRON) https://sec-api.dev/companies/iron/catalysts |
| Indications | [scd in october 2025, with initial data](https://sec-api.dev/indications/scd-in-october-2025-with-initial-data), polycythemia vera with initial data, pv with initial data, [scd in october 2025 with initial data](https://sec-api.dev/indications/scd-in-october-2025-with-initial-data), pv, in june 2025, with initial data, [Polycythemia Vera (PV)](https://sec-api.dev/indications/polycythemia-vera-pv) |
| Modality |  |
| FDA designations | fast track |

## Timeline

### Oct 2023: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2024-11-12, last confirmed 2025-11-06.
- SEC Form 10-Q (accession 0001193125-25-268200): "In October 2023, the Company dosed the first patient in the Phase 1 clinical trial for DISC-3405, resulting in a milestone payment of $5.0 million to Mabwell." https://www.sec.gov/Archives/edgar/data/1816736/000119312525268200/iron-20250930.htm
- SEC Form 10-Q (accession 0001816736-25-000007): "In October 2023, the Company dosed the first patient in the Phase 1 clinical trial for DISC-3405, resulting in a milestone payment of $5.0 million to Mabwell." https://www.sec.gov/Archives/edgar/data/1816736/000181673625000007/iron-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-065069): "In October 2023, the Company dosed the first patient in the Phase 1 clinical trial for DISC-3405, resulting in a milestone payment of $5.0 million to Mabwell." https://www.sec.gov/Archives/edgar/data/1816736/000095017025065069/iron-20250331.htm
- SEC Form 10-K (accession 0000950170-25-028390): "In October 2023, the Company dosed the first patient in the Phase 1 clinical trial for DISC-3405, resulting in a milestone payment of $5.0 million to Mabwell." https://www.sec.gov/Archives/edgar/data/1816736/000095017025028390/iron-20241231.htm
- SEC Form 10-Q (accession 0000950170-24-124650): "In October 2023, the Company dosed the first patient in the Phase 1 clinical trial for DISC-3405, resulting in a milestone payment of $5.0 million due to Mabwell." https://www.sec.gov/Archives/edgar/data/1816736/000095017024124650/iron-20240930.htm
- SEC Form 10-Q (accession 0000950170-24-124650): "Additionally, we initiated a Phase 1 clinical trial of DISC-3405 in healthy adult volunteers in October 2023, which may not be indicative or predictive of future clinical trial results." https://www.sec.gov/Archives/edgar/data/1816736/000095017024124650/iron-20240930.htm

### 2H 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-01-10, last confirmed 2025-05-07.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-065031): "We expect data from ongoing trials of DISC-0974, the Phase 2 MF anemia study and the Phase 1b NDD-CKD anemia study, to read out in the second half of this year and expect to initiate a Phase 2 study of DISC-3405 in PV in the coming months."" https://www.sec.gov/Archives/edgar/data/1816736/000095017025065031/iron-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-065031): "Plan to initiate Phase 2 study of DISC-3405 in polycythemia vera (PV) in H1 2025" https://www.sec.gov/Archives/edgar/data/1816736/000095017025065031/iron-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-003859): "Initiation of phase 2 study of DISC-3405 (anti-TMPRSS6 antibody) in polycythemia vera (PV) planned for H1 2025" https://www.sec.gov/Archives/edgar/data/1816736/000095017025003859/iron-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-003859): "Plan to initiate phase 2 clinical trial of DISC-3405 in PV in H1 2025" https://www.sec.gov/Archives/edgar/data/1816736/000095017025003859/iron-ex99_1.htm
- SEC Form 10-Q (accession 0000950170-25-065069): "We expect to develop DISC-3405 for the treatment of PV and other hematologic disorders and plan to initiate a Phase 2 clinical trial of DISC-3405 in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1816736/000095017025065069/iron-20250331.htm
- SEC Form 10-K (accession 0000950170-25-028390): "We expect to develop DISC-3405 for the treatment of PV and other hematologic disorders, and plan to initiate a Phase 2 clinical trial of DISC-3405 in PV in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1816736/000095017025028390/iron-20241231.htm
- SEC Form 10-K (accession 0000950170-25-028390): "We expect to develop DISC-3405 for the treatment of PV and other hematologic disorders, and plan to initiate a Phase 2 clinical trial of DISC-3405 in PV in the first half of 2025 and report data in 2026." https://www.sec.gov/Archives/edgar/data/1816736/000095017025028390/iron-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-065031): "On track to initiate Phase 2 study in PV in H1 2025" https://www.sec.gov/Archives/edgar/data/1816736/000095017025065031/iron-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-037650): "The Company plans to initiate a Phase 2 study in PV in H1 2025" https://www.sec.gov/Archives/edgar/data/1816736/000119312525037650/d916827dex991.htm

### Oct 2025: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: SCD in October 2025 with initial data.
- First seen 2025-11-06, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-268196): "Initiated Phase 1b study of DISC-3405 in patients with SCD in October 2025 with initial data expected in 2026" https://www.sec.gov/Archives/edgar/data/1816736/000119312525268196/iron-ex99_1.htm
- SEC Form 10-K (accession 0001193125-26-073602): "With respect to DISC-3405, we initiated a Phase 1b, open-label clinical trial in patients with SCD in October 2025, with initial data expected in the second half of 2026, and plan to explore the role of therapeutic iron restriction in other indications." https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm

### 2026: topline data readout

- Status: scheduled. Date confidence: year. Stage: 2.
- First seen 2025-10-20, last confirmed 2025-10-20.
- SEC Form 8-K (accession 0001193125-25-242959): "Topline data from ongoing Phase 2 study in PV expected in 2026" https://www.sec.gov/Archives/edgar/data/1816736/000119312525242959/d272031d8k.htm

### Q3 2026: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 1. Indication: polycythemia vera with initial data.
- First seen 2026-07-30, last confirmed 2026-07-30.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-325031): "Completed enrollment for RESTORE-PV Phase 2 study of DISC-3405 in polycythemia vera (PV) with initial data expected in Q3 2026 and progressing Phase 1b study of DISC-3405 in sickle cell disease (SCD) with initial data expected in Q4 2026" https://www.sec.gov/Archives/edgar/data/1816736/000119312526325031/iron-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-325034): "We initiated RESTORE-PV, an open-label Phase 2 clinical trial of DISC-3405 in patients with PV, in June 2025, with initial data expected in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1816736/000119312526325034/iron-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-325031): "Completed enrollment for RESTORE-PV Phase 2 study in patients with polycythemia vera with initial data expected in Q3 2026" https://www.sec.gov/Archives/edgar/data/1816736/000119312526325031/iron-ex99_1.htm

### Q4 2026: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 1. Indication: SCD in October 2025, with initial data.
- First seen 2025-08-07, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-387351): "Disc plans to provide an update on RESTORE-PV, as well as initial data from the Phase 1b trial of DISC-3405 in sickle cell disease, by the end of 2026." https://www.sec.gov/Archives/edgar/data/1816736/000119312526387351/iron-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-268196): "Initiated Phase 1b study of DISC-3405 in patients with SCD in October 2025 with initial data expected in 2026" https://www.sec.gov/Archives/edgar/data/1816736/000119312525268196/iron-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-448729): "We also initiated a Phase 1b, open-label clinical trial of DISC-3405 in patients with SCD in October 2025, with initial data expected in the fourth quarter of 2026, and plan to explore the role of therapeutic iron restriction in other indications." https://www.sec.gov/Archives/edgar/data/1816736/000119312526448729/iron-20260930.htm
- SEC prospectus (424B) (accession 0001193125-26-427982): "We also initiated a Phase 1b, open-label clinical trial of DISC-3405 in patients with SCD in October 2025, with initial data expected in the fourth quarter of 2026, and plan to explore the role of therapeutic iron restriction in other indications." https://www.sec.gov/Archives/edgar/data/1816736/000119312526427982/d190758d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-425425): "We also initiated a Phase 1b, open-label clinical trial of DISC-3405 in patients with SCD in October 2025, with initial data expected in the fourth quarter of 2026, and plan to explore the role of therapeutic iron restriction in other indications." https://www.sec.gov/Archives/edgar/data/1816736/000119312526425425/d190758d424b5.htm
- SEC Form 10-Q (accession 0001193125-26-325034): "We also initiated a Phase 1b, open-label clinical trial of DISC-3405 in patients with SCD in October 2025, with initial data expected in the fourth quarter of 2026, and plan to explore the role of therapeutic iron restriction in other indications." https://www.sec.gov/Archives/edgar/data/1816736/000119312526325034/iron-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-205192): "We also initiated a Phase 1b, open-label clinical trial of DISC-3405 in patients with SCD in October 2025, with initial data expected in the fourth quarter of 2026, and plan to explore the role of therapeutic iron restriction in other indications." https://www.sec.gov/Archives/edgar/data/1816736/000119312526205192/iron-20260331.htm
- SEC Form 10-K (accession 0001193125-26-073602): "We also initiated a Phase 1b, open-label clinical trial of DISC-3405 in patients with SCD in October 2025, with initial data expected in the second half of 2026, and plan to explore the role of therapeutic iron restriction in other indications." https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm
- SEC Form 10-K (accession 0001193125-26-073602): "With respect to DISC-3405, we initiated a Phase 1b, open-label clinical trial in patients with SCD in October 2025, with initial data expected in the second half of 2026, and plan to explore the role of therapeutic iron restriction in other indications." https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-205187): "Progressing ongoing Phase 2 study in patients with polycythemia vera and Phase 1b study in patients with sickle cell disease with initial data expected in Q4 2026" https://www.sec.gov/Archives/edgar/data/1816736/000119312526205187/iron-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-25-268200): "We also initiated a Phase 1b clinical trial of DISC-3405 in patients with SCD in October 2025, with initial data expected in 2026, and plan to explore the role of therapeutic iron restriction in other indications." https://www.sec.gov/Archives/edgar/data/1816736/000119312525268200/iron-20250930.htm
- SEC Form 10-K (accession 0001193125-26-073602): "We are currently studying DISC-3405 in RESTORE-PV, an open-label Phase 2 clinical trial of DISC-3405 in patients with PV, from which we expect initial data in the second half of 2026 and topline data in 2027." https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm

### July 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Polycythemia Vera (PV).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06985147 (A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Disc Medicine, Inc." https://clinicaltrials.gov/study/NCT06985147

### Jul to Oct 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Polycythemia Vera (PV).
- First seen 2026-11-05, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06985147 (A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Disc Medicine, Inc." https://clinicaltrials.gov/study/NCT06985147
- SEC Form 10-Q (accession 0001193125-26-448729): "We expect to report additional data from our RESTORE-PV clinical trial by the end of 2026 and topline data in 2027." https://www.sec.gov/Archives/edgar/data/1816736/000119312526448729/iron-20260930.htm
- SEC prospectus (424B) (accession 0001193125-26-450184): "We expect to report additional data from our RESTORE-PV clinical trial by the end of 2026 and topline data in 2027." https://www.sec.gov/Archives/edgar/data/1816736/000119312526450184/d187305d424b5.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/disc-3405.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "DISC-3405 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/disc-3405

```bibtex
@misc{secapidev_pdufa_disc_3405_20261116,
  title        = {DISC-3405 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/disc-3405}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_disc_3405_20261116","title":"DISC-3405 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/disc-3405","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
